Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInnoviva Inc

Innoviva Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
19.1 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1654267
Market Cap
1505.60M
P/E
4.85

Momentum Score

…

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
19.02
Low
19.87
High
52 Week Price Range
16.52
Low
25.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
19.10
Dividend Yield
-
Revenue TTM
440.00M
Revenue Per Share
6.04
Gross Profit TTM
319.75M
Debt / Equity
0.23
ROE
36.68%
Net Debt
-281.92M
ROCE
21.67%
Diluted EPS TTM
4.30

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 326.86M 37.39M 194.10M 286.95M 445.28M
Minority interest - 0.00M 0.00M -6.34M 102.98M
Net income 271.17M 23.39M 179.72M 213.92M 265.85M
Selling general administrative 113.32M 115.69M 89.37M 63.54M 16.19M
Gross profit 307.52M 322.11M 267.82M 317.55M 391.87M
Reconciled depreciation 26.28M 25.90M 33.27M 5.58M 13.83M
Ebit 343.56M 59.60M 213.25M 209.99M 426.21M
Ebitda 383.79M 85.50M 235.04M 215.57M 361.36M
Depreciation and amortization 40.23M 25.90M 21.78M 5.58M 13.83M
Non operating income net other - - - - 87.40M
Operating income 163.75M 166.87M 113.89M 209.99M 375.10M
Other operating expenses 261.38M 191.84M 196.58M 124.34M 16.76M
Interest expense 16.70M 22.21M 19.16M 15.79M 19.07M
Tax provision 55.70M 14.00M 18.33M 66.69M 76.44M
Interest income 21.09M 19.14M 14.22M 6.37M 1.84M
Net interest income 4.39M -3.07M -3.01M -9.42M -17.23M
Income tax expense 55.70M 14.00M 14.38M 66.69M 76.44M
Total revenue 425.13M 358.71M 310.46M 331.34M 391.87M
Total operating expenses 143.77M 155.25M 153.94M 110.55M 16.76M
Cost of revenue 117.61M 36.60M 42.64M 13.79M -
Total other income expense net 163.12M -129.48M 80.21M 76.96M 70.17M
Net income from continuing ops 271.17M 23.39M 49.88M 220.26M 368.84M
Net income applicable to common shares - - - 213.92M 265.85M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1635.16M 1301.06M 1243.51M 1231.50M 926.39M
Intangible assets 182.16M 208.43M 230.34M 252.92M -
Other current assets 102.44M 21.72M 25.89M 32.49M 112.15M
Total liab 462.32M 609.90M 568.55M 665.71M 400.46M
Total stockholder equity 1172.84M 691.16M 674.96M 565.79M 414.74M
Deferred long term liab - - - 97.61M 111.43M
Other current liab 39.77M -14.00M 28.93M -63.77M 5.78M
Common stock 0.75M 0.63M 0.63M 0.69M 0.70M
Capital stock 0.75M 0.63M 0.63M 0.69M 0.70M
Retained earnings 269.37M -1.80M -25.19M -204.91M -456.15M
Other liab - - - 84.19M -
Good will 17.91M 17.91M 17.91M 26.71M -
Other assets - - - 198.47M 425.21M
Cash 550.94M 304.96M 193.51M 291.05M 201.53M
Total current liabilities 49.70M 236.08M 38.13M 38.77M 5.81M
Current deferred revenue 4.27M 1.13M 1.28M 2.09M -
Net debt -281.92M 146.13M 255.56M 346.83M 193.13M
Short term debt 0.42M 193.60M 1.21M 97.51M -
Short long term debt - 192.03M - 96.19M -
Short long term debt total 269.02M 451.10M 449.08M 637.88M 394.65M
Other stockholder equity 902.73M 692.33M 699.51M 770.01M 870.20M
Property plant equipment - - - 3.44M 0.01M
Total current assets 727.51M 554.31M 344.22M 443.51M 313.67M
Long term investments 598.22M 393.96M 560.98M 403.01M 483.85M
Net tangible assets - - - 286.16M 414.74M
Short term investments 15.73M 107.53M - 403.01M 483.85M
Net receivables 34.97M 86.37M 84.08M 64.07M 110.71M
Long term debt 257.73M 256.32M 446.23M 540.37M 394.65M
Inventory 39.17M 33.73M 40.74M 55.90M -110.71M
Accounts payable 4.97M 2.13M 6.72M 2.94M 0.03M
Noncontrolling interest in consolidated entity - - - - 111.19M
Accumulated other comprehensive income - - 0.00M - -
Common stock total equity - - - - 0.70M
Retained earnings total equity - - - - -456.15M
Non currrent assets other 501.38M 111.44M 87.05M 101.91M 0.11M
Non current assets total 907.65M 746.75M 899.29M 787.99M 612.72M
Capital lease obligations 11.29M 2.75M 2.84M 3.69M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 22.82M -63.79M -70.29M -56.63M 43.72M
Change to liabilities - - - -0.66M -0.04M
Total cashflows from investing activities 40.50M -63.79M - -56.63M 43.72M
Net borrowings 0.00M 0.00M - 87.41M 87.41M
Total cash from financing activities 8.55M -13.45M -171.84M -55.57M -452.50M
Change to operating activities - - - -12.57M -0.05M
Net income 271.17M 23.39M 179.72M 220.26M 368.84M
Change in cash 245.98M 111.45M -97.54M 89.52M -44.96M
Begin period cash flow 304.96M 193.51M 291.05M 201.53M 246.49M
End period cash flow 550.94M 304.96M 193.51M 291.05M 201.53M
Total cash from operating activities 196.93M 188.69M 141.06M 201.73M 363.81M
Issuance of capital stock 2.55M 1.47M 0.14M 0.37M 1.17M
Depreciation 40.23M 39.85M 35.70M 19.51M 13.83M
Other cashflows from investing activities -9.36M -3.90M - - -67.12M
Dividends paid - - 96.28M - 0.00M
Change to inventory -12.92M -6.81M -12.00M 0.28M 0.28M
Change to account receivables -6.95M -2.29M -20.00M 9.79M -16.78M
Sale purchase of stock -4.67M -14.92M -75.81M -8.59M -394.21M
Other cashflows from financing activities 8.55M -13.45M 96.28M 117.78M -59.46M
Change to netincome - - - -40.63M 91.86M
Capital expenditures 10.50M 0.27M 0.41M 0.07M 1.30M
Change receivables - - - - -16.78M
Cash flows other operating - - - - 0.20M
Cash and cash equivalents changes - - - - -44.96M
Change in working capital -24.16M -6.93M -24.79M 6.87M -16.87M
Stock based compensation 9.45M 6.37M 5.84M 7.35M 2.02M
Other non cash items -143.60M 138.62M -59.81M -77.27M -80.43M
Free cash flow 186.43M 188.42M 140.65M 201.66M 362.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INVA
Innoviva Inc		 -
-%		 19.10 4.85 8.82 3.42 1.23 2.73 2.59
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Innoviva Inc

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

1350 Old Bayshore Highway, Burlingame, CA, United States, 94010

650 238 9600

https://www.inva.com

159

Name Title Year Born
Mr. Pavel Raifeld C.F.A. Chief Exec. Officer 1984
Ms. Marianne Zhen CPA Chief Accounting Officer & Sec. 1969
Mr. Pavel Raifeld C.F.A. Chief Executive Officer 1984
Ms. Marianne Zhen CPA Chief Accounting Officer & Secretary 1969
Mr. Stephen Basso M.B.A. Chief Financial Officer 1966
Mr. Pavel Raifeld C.F.A. CEO & Director 1984
Ms. Patricia M. Drake Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. 1967
Dr. David Altarac M.D., MPA Chief Medical Officer of IST 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…